AI Prospecting for Biogen
Company data:
Company size:
7570 employeesWebsite URL:
https://www.biogen.comIndustry
BiotechnologyHeadquarters:
Cambridge, Massachusetts, USAInvestment round:
Publicly Traded (NASDAQ: BIIB)ARR:
$11 billionLatest news about Biogen
Here are some of the most recent media mentions. Use them in your sales prospecting to qualify a prospect's buyer intent and personalize outreach with the latest company updates
Biogen and Eisai's Leqembi (lecanemab) has been authorized in the European Union as the first medicine to slow the progression of early Alzheimer's disease, following recent regulatory approvals and ongoing advancements in subcutaneous and blood-based biomarker developments[1][5].
Biogen's investigational tau-targeting therapy, BIIB080, an antisense oligonucleotide (ASO), has received FDA Fast Track designation for the treatment of Alzheimer's disease. It is the first tau-targeting ASO in clinical development and is currently being evaluated in the Phase 2 CELIA study for early-stage Alzheimer's disease[4][5].
Biogen has initiated a Phase 3 study of felzartamab for the treatment of late antibody-mediated rejection (AMR) in kidney transplant patients, marking a significant advancement in their clinical trials portfolio[1].
Open job positions at Biogen
This company is actively hiring to fill these roles. Use this for sales prospecting if your solution assists, augments, or provides an alternative for the growing team and position.
Neurology Account Manager - Minneapolis
Neurology Account Manager
Senior Manager, Payer Marketing
